Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

InMed Pharmaceuticals Inc INM

InMed Pharmaceuticals Inc. is a pharmaceutical company. It develops a pipeline of small molecule drug candidates targeting the CB1/CB2 receptors. Its InMed Pharmaceuticals segment is engaged in the research and development of small molecule pharmaceuticals drug candidates. Its BayMedica Commercial segment is engaged in the manufacturing technologies to produce and commercialize bulk rare cannabinoids for sale as ingredients in the health and wellness industry. Its pharmaceutical pipeline consists of three programs, with drug candidates targeting Alzheimer’s disease, dry age-related macular degeneration, and Epidermolysis Bullosa. Its INM-901 is a drug candidate being developed as a potential treatment for Alzheimer’s disease. Its INM-089 is cannabinoid analog being studied for its potential as a treatment for age-related macular degeneration. Its INM-755 is a cannabinol topical cream which has completed Phase 2 clinical trial studies for the treatment of epidermolysis bullosa.


NDAQ:INM - Post by User

Bullboard Posts
Post by Moneymagnet14on Sep 18, 2014 6:23pm
229 Views
Post# 22949996

CAN

CAN"One of Craig's first companies that he worked for was Ultra Petroleum. The stock dropped from .95 to .45 before blasting through the stratosphere to a stunning pre split price of close to $200. Put another way, the market cap rose from around $3 million to close to $3 Billion! Loyal investors were rewarded once again in 2006, as he was the cofounder of Magnum Uranium, which was taken over by Energy Fuels in 2009. Shareholders were once again exposed to another potential 1000% gain by 2011." Ultra Petroleum Market Cap: $3.8 Billion 10 Year high: $102.81 Todays price: $24.79 Ultra Petroleum Corporation History The two Bohai Bay fields drilled their first wells in July 2004, initially producing some 30,000 barrels of oil a day with expectations that the level would increase to 65,000 barrels in 2005. All told in 2004, Ultra increased its production through the drill bit by more than 70 percent. Coupled with higher oil and gas prices, the company also experienced an exceptional year financially, posting revenues of $258 million and net income of $109.1 million. https://www.fundinguniverse.com/company-histories/ultra-petroleum-corporation-history/ ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ Energy Fuels 10 year high: $274 Todays price: $8.20 Energy Fuels Announces Closing of Merger with Magnum Uranium Corp. TORONTO, ONTARIO -- (MARKET WIRE) -- 07/02/09 -- Energy Fuels Inc. (TSX: EFR) ("Energy Fuels" or the "Company") is pleased to announce that the merger of Energy Fuels and Magnum Uranium Corp. was successfully completed effective June 30, 2009. With the closing of this transaction, Magnum shareholders became shareholders of Energy Fuels on the basis of 0.78 shares of Energy Fuels for each Magnum common share held.
Bullboard Posts